Novo claim study confirms diabetes drug weight gain inhibition

According to major diabetes pharmaceutical company Novo Nordisk, a new study confirms that their new diabetes treatment Levemir actually serves to limit weight gain amongst diabetic patients.
The study, conducted by experts at the Royal Surrey County Hospital, confirms Novo Nordisk expectations for their drug. The study was called PREDICTIVE, and served to examine how Levemir affected over 20,000 people suffering from type 1 and type 2. Diabetics participating in the study, from 11 different countries, indicated that the drug decreased body weight and improved blood glucose levels.
According to one expert involved in the study, Professor Russell-Jones: “Insulin initiation is often associated with considerable weight gain . The reduced risk of weight gain that Levemir offers potentially provides people with diabetes an enhanced treatment option.”